GE HealthCare and Raydiant Oximetry are joining forces to advance a breakthrough technology aimed at improving the detection of foetal distress.
The partnership means that Raydiant’s Lumerah foetal pulse oximetry technology will be integrated into GE HealthCare’s foetal monitoring and digital perinatal surveillance platforms.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Raydiant’s Lumerah is a non-invasive, transabdominal foetal pulse oximeter designed to improve the detection of foetal distress during labour and delivery by measuring foetal blood oxygen saturation.
The clinical stage medtech company’s oximeter received an investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) in 2024. Initial clinical studies of the device have found that it can help to improve the sensitivity in detecting foetal distress during labour and delivery, thereby informing clinician actions that may help to reduce newborn neurological injury rates and a need for emergency caesarean section deliveries.
According to the companies, the incorporation of oxygen saturation detection technology into broader foetal monitoring elevates clinician confidence when critical decisions are being made during labour.
Providing a more comprehensive view of foetal well-being to improve clinicians’ evaluation of foetal status is also expected to help in reducing emergency caesarean section rates, which research indicates have been increasing beyond levels considered medically necessary in recent decades.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLarry Boyd, general manager of maternal infant care at GE HealthCare commented: “Together with Raydiant Oximetry, we are proud to be at the forefront of this technology to help clinicians better manage the complexities of perinatal care.
“We are excited about the potential of this technology to complement our current perinatal portfolio and help us enable care that can support every pivotal moment in labour and delivery, for every family and baby.”
Founded in 2015, California-based Raydiant completed an extended Series A financing round last year, bringing its total funding to date to around $17m.
Dr Neil P Ray, founder and CEO of Raydiant, stated that GE HealthCare’s deep knowledge of the foetal monitoring space would help the company to advance its technology and meet its aims to “transform the standard of care” in foetal monitoring.
